Prenetics Global Limited (PRE)

Market Cap	69.70M
Revenue (ttm)	25.56M
Net Income (ttm)	-46.91M
Shares Out	12.22M
EPS (ttm)	-3.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,774
Open	5.79
Previous Close	5.71
Day's Range	5.71 - 5.88
52-Week Range	2.85 - 7.84
Beta	-0.19
Analysts	Buy
Price Target	9.00 (+57.76%)
Earnings Date	Nov 27, 2024

About PRE

Prenetics Global Limited, a health sciences company, focuses on advancing consumer and clinical health. The company’s consumer initiatives is led by IM8, a new health and wellness brand. Its prevention arm, CircleDNA, uses next-generation sequencing (NGS) technology to offer comprehensive consumer DNA test. It also develops and commercializes multi-cancer early detection technologies. In addition, the company offers a range of genomic profiling panels tailored for requirements and clinician needs, including ACTOnco, ACT HRD, ACTFusion, and ACTD...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2014
• Employees: 324
• Stock Exchange: NASDAQ
• Ticker Symbol: PRE
• Website: https://www.prenetics.com

Financial Performance

In 2023, Prenetics Global's revenue was $21.74 million, an increase of 65.17% compared to the previous year's $13.16 million. Losses were -$62.72 million, -67.07% less than in 2022.

Analyst Forecast

According to one analyst, the rating for PRE stock is "Buy" and the 12-month stock price forecast is $9.0.

Price Target

$9.0

(57.76% upside)

Analyst Consensus: Buy